Washington, D.C. 20549
Indicate by check mark whether registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes R No £
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes R No £
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes £ No R
The number of shares outstanding of the issuer’s common stock, $0.001 value per share, as of June 1, 2014 was 25,333,479 shares.
SYNERGETICS USA, INC.
Synergetics USA, Inc. and Subsidiaries
See Notes to Unaudited Condensed Consolidated Financial Statements.
Synergetics USA, Inc. and Subsidiaries
See Notes to Unaudited Condensed Consolidated Financial Statements.
Synergetics USA Inc. and Subsidiaries
See Notes to Unaudited Condensed Consolidated Financial Statements.
Synergetics USA, Inc. and Subsidiaries
(Tabular information reflects dollars in thousands, except share and per share information)
Note 1. General
Note 2. Summary of Significant Accounting Policies
The Company’s significant accounting policies are disclosed in the Annual Report. In the first nine months of fiscal 2014, no significant accounting policies were changed.
On October 1, 2013, the Company announced plans to close its King of Prussia, Pennsylvania facility and consolidate the manufacturing operations into its existing facility in O’Fallon, Missouri. The Company expects to complete the closure over the next 8 months. Costs are recognized in “Exit costs” in the consolidated statements of income and comprehensive income. As of April 30, 2014, the Company had a current liability of $177,000 for employee termination benefits in accrued expenses.
|
|
|
Three Months
Ended April 30,
|
|
|
Nine Months
Ended April 30,
|
|
|
|
|
|
|
|
|
|
|
2014
|
|
|
2013
|
|
|
2014
|
|
|
2013
|
|
|
Cumulative as of April 30, 2014
|
|
|
Total Expected
to be Incurred
|
|
|
Employee termination benefits
|
|
$
|
34
|
|
|
$
|
--
|
|
|
$
|
533
|
|
|
$
|
--
|
|
|
$
|
533
|
|
|
$
|
1,085
|
|
|
Other associated costs
|
|
|
30
|
|
|
|
--
|
|
|
|
45
|
|
|
|
--
|
|
|
|
45
|
|
|
|
79
|
|
|
|
|
$
|
64
|
|
|
$
|
--
|
|
|
$
|
578
|
|
|
$
|
--
|
|
|
$
|
578
|
|
|
$
|
1,164
|
|
|
|
|
Termination Costs
|
|
|
Exit Liabilities at October 1, 2013
|
|
$
|
--
|
|
|
Additions
|
|
|
514
|
|
|
Payments
|
|
|
(273
|
)
|
|
Exit Liabilities at January 31, 2014
|
|
|
241
|
|
|
Additions
|
|
|
64
|
|
|
Payments
|
|
|
(128
|
)
|
|
Exit Liabilities at April 30, 2014
|
|
$
|
177
|
|
Note 4. Acquisition of M.I.S.S. Ophthalmics Limited
On July 8, 2013, a subsidiary of the Company acquired M.I.S.S. Ophthalmics Limited (“M.I.S.S.”), a private ophthalmology distribution company incorporated in England and Wales, for net cash consideration of $2.8 million. M.I.S.S. was the Company’s distributor of ophthalmic products in the United Kingdom, and its wholesale distribution activities contributed approximately $1.1 million in revenue to the Company in fiscal 2013. M.I.S.S. generated total revenue of approximately $3.2 million during its fiscal year ended March 31, 2013.
The Company has allocated the purchase price to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair value at the date of acquisition resulting in the recognition of $0.9 million of intellectual property and $1.5 million of goodwill.
No supplemental pro-forma information is presented for the acquisition due to the immaterial effect of the acquisition on the Company's financial statements.
Note 5. OEM Partner Agreements
The Company sells all of its generators and a majority of its neurosurgery instruments and accessories to two U.S.-based national and international original equipment manufacturer (“OEM”) partners as described below:
Codman & Shurtleff, Inc. (“Codman”)
In the neurosurgical market, the bipolar electrosurgical system manufactured by the Company has been sold for over 30 years through a series of distribution agreements with Codman, an affiliate of Johnson & Johnson. Pursuant to a distribution agreement with Codman, Codman has exclusive rights to distribute certain of the Company’s electrosurgery generators and related disposables and accessories, as well as the SpetzlerTM-Malis® branded disposable bipolar forceps produced by Synergetics. Codman markets and distributes these products both domestically and internationally. In addition, the Company has granted Codman a license to use the Company’s Malis® trademark with certain Codman products, including those covered by the distribution agreement. The distribution and licensing agreements both expire at the end of calendar 2014.
Total sales to Codman and its respective percent of the Company’s net sales for the three and nine months ended April 30, 2014 and 2013, including the sales of generators, accessories and disposable cord tubing that the Company has supplied in the past, as well as the disposable bipolar forceps sales resulting from the addendum to the existing distribution agreement, were as follows (dollars in thousands):
|
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Net Sales
|
|
$
|
3,827
|
|
|
$
|
3,905
|
|
|
$
|
11,018
|
|
|
$
|
9,677
|
|
|
Percent of net sales
|
|
|
23.7
|
%
|
|
|
24.0
|
%
|
|
|
23.6
|
%
|
|
|
21.5
|
%
|
Stryker Corporation (“Stryker”)
The Company supplies a multi-channel ablation generator, used for minimally invasive pain treatment, to Stryker pursuant to a supply and distribution agreement that expires on June 30, 2015. The Company also maintains a supply agreement with Stryker pursuant to which the Company supplies Stryker with disposable ultrasonic aspirator instrument tips and certain other consumable products used in conjunction with Stryker’s ultrasonic aspirator console and handpieces. This agreement expires on March 31, 2016.
Total sales to Stryker and its respective percent of the Company’s net sales for the three and nine months ended April 30, 2014 and 2013, including the sales of pain control generators and accessories that the Company has supplied in the past, as well as the disposable ultrasonic instrument tips sales and certain other consumable products resulting from the agreements, were as follows (dollars in thousands):
|
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Net Sales
|
|
$
|
3,185
|
|
|
$
|
3,094
|
|
|
$
|
7,798
|
|
|
$
|
7,472
|
|
|
Percent of net sales
|
|
|
19.7
|
%
|
|
|
19.0
|
%
|
|
|
16.7
|
%
|
|
|
16.6
|
%
|
No other customer comprises more than 10 percent of sales in any given quarter.
Note 6. Stock-Based Compensation
Stock Option Plans
The following table provides information about stock-based awards outstanding at April 30, 2014:
|
|
|
Shares
|
|
|
Weighted Average Exercise Price
|
|
|
Weighted Average Fair Value
|
|
|
Options outstanding beginning of period
|
|
|
747,662
|
|
|
$
|
4.17
|
|
|
$
|
3.23
|
|
|
For the period August 1, 2013 through April 30, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
117,500
|
|
|
$
|
3.64
|
|
|
$
|
2.72
|
|
|
Forfeited
|
|
|
--
|
|
|
|
--
|
|
|
|
--
|
|
|
Exercised
|
|
|
(30,000
|
)
|
|
$
|
1.20
|
|
|
$
|
1.00
|
|
|
Options outstanding, end of period
|
|
|
835,162
|
|
|
$
|
4.17
|
|
|
$
|
3.22
|
|
|
Options exercisable, end of period
|
|
|
602,299
|
|
|
$
|
4.00
|
|
|
$
|
3.11
|
|
During the second quarter of fiscal 2014, there were options to purchase 60,000 shares of Common Stock granted to the Company’s independent directors, which vest pro-ratably on a quarterly basis over the next year of service. Each independent director receives an option to purchase 10,000 shares of the Company’s Common Stock each year in which he or she is elected, appointed or continues to serve as a director pursuant to the Amended and Restated 2005 Non-Employee Directors’ Stock Option Plan, as amended. These options also vest upon a change of control event. The Company recorded $39,000 and $53,000 of compensation expense for the three and nine months ended April 30, 2014, respectively, for these options. The Company recorded $71,000 of compensation expense for the nine months ended April 30, 2014 for previously granted director options.
During the second quarter of fiscal 2014, there were options to purchase 57,500 shares of Common Stock granted to the officers and certain employees of the Company. These options were granted in conjunction with the Company’s annual review of compensation as of August 1, 2013 and vest on a quarterly basis over the next four years of service. The Company recorded $10,000 and $14,000 of compensation expense for the three and nine months ended April 30, 2014, respectively, for these options. The Company recorded $56,000 and $284,000 of compensation expense for three and nine months ended April 30, 2014, respectively, for previously granted officer and employee options. As a result of the King of Prussia facility closure, $101,000 of this compensation expense is included in exit costs for the nine months ended April 30, 2014.
The Company expects to issue new shares as options are exercised. As of April 30, 2014, the future compensation cost expected to be recognized for currently outstanding stock options is approximately $106,000 for the remainder of fiscal 2014, $324,000 in fiscal 2015, $238,000 in fiscal 2016, $119,000 in fiscal 2017 and $17,000 in fiscal 2018.
The fair value of all options granted during the second quarter of fiscal 2014 was determined at the date of the grant using the Black-Scholes option-pricing model and the following assumptions:
|
Expected average risk-free interest rate
|
2.9%
|
|
Expected average life (in years)
|
10
|
|
Expected volatility
|
68.6%
|
|
Expected dividend yield
|
0.0%
|
The expected average risk-free rate is based on the 10-year U.S. treasury yield curve in December 2013. The expected average life represents the period of time that the options granted are expected to be outstanding giving consideration to the vesting schedules, historical exercises and forfeiture patterns. Expected volatility is based on historical volatilities of the Company’s Common Stock. The expected dividend yield is based on historical information and management’s plan.
The fair value of the in-the-money stock options outstanding was $244,000 and $273,000 at April 30, 2014 and 2013, respectively. The fair value of in-the-money exercisable stock options was $236,000 and $248,000 at April 30, 2014 and 2013, respectively.
Restricted Stock Plans
Under the Company’s Second Amended and Restated Synergetics USA, Inc. 2001 Stock and Performance Incentive Plan (“2001 Plan”), the Company’s Common Stock may be granted at no cost to certain employees and consultants of the Company. Certain plan participants are entitled to cash dividends and voting rights for their respective shares. Restrictions limit the sale or transfer of these shares during a vesting period whereby the restrictions lapse either pro-ratably over a three-year to five-year period or at the end of the third, fourth or fifth year. These shares also vest upon a change of control event. Upon issuance of stock under the 2001 Plan, unearned compensation equivalent to the market value at the date of the grant is charged to stockholders’ equity and subsequently amortized to expense over the applicable restriction period. As of April 30, 2014, there was approximately $662,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2001 Plan. The cost is expected to be recognized over a weighted average period of four years which is generally the vesting period. The Company recorded $82,000 and $344,000 of compensation expense for three and nine months ended April 30, 2014, respectively. As a result of the King of Prussia facility closure, $100,000 of this compensation expense is included in exit costs for the nine months ended April 30, 2014. The following table provides information about restricted stock grants during the nine months ended April 30, 2014:
|
|
|
Number of Shares
|
|
|
Weighted Average Grant Date Fair Value
|
|
|
Balance as of July 31, 2013
|
|
|
405,248
|
|
|
$
|
3.79
|
|
|
Granted
|
|
|
7,000
|
|
|
$
|
3.38
|
|
|
Forfeited
|
|
|
(2,335
|
)
|
|
$
|
3.88
|
|
|
Vested
|
|
|
(134,366
|
)
|
|
$
|
4.52
|
|
|
Balance as of April 30, 2014
|
|
|
275,547
|
|
|
$
|
3.42
|
|
Note 7. Fair Value Information
Fair value is an exit price that represents the amount that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants.
The Company does not have any financial assets which are required to be measured at fair value on a recurring basis. Non-financial assets such as goodwill, intangible assets and property, plant and equipment are measured at fair value when there is an indicator of impairment or at least annually and recorded at fair value only when impairment is recognized. No impairment indicators existed as of April 30, 2014.
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short maturity of these items.
Note 8. Supplemental Balance Sheet Information
Inventories: Inventories as of April 30, 2014 and July 31, 2013, respectively, were as follows:
|
|
|
April 30, 2014
|
|
|
July 31, 2013
|
|
|
Raw material and component parts
|
|
$
|
7,775
|
|
|
$
|
7,418
|
|
|
Work in progress
|
|
|
1,537
|
|
|
|
1,133
|
|
|
Finished goods
|
|
|
6,399
|
|
|
|
6,274
|
|
|
|
|
$
|
15,711
|
|
|
$
|
14,825
|
|
Property and Equipment: Property and equipment as of April 30, 2014 and July 31, 2013, respectively, were as follows:
|
|
|
April 30, 2014
|
|
|
July 31, 2013
|
|
|
Land
|
|
$
|
730
|
|
|
$
|
730
|
|
|
Building and improvements
|
|
|
6,865
|
|
|
|
6,365
|
|
|
Machinery and equipment
|
|
|
8,983
|
|
|
|
8,665
|
|
|
Furniture and fixtures
|
|
|
1,090
|
|
|
|
1,058
|
|
|
Software
|
|
|
1,113
|
|
|
|
1,107
|
|
|
Construction in progress
|
|
|
141
|
|
|
|
177
|
|
|
|
|
|
18,922
|
|
|
|
18,102
|
|
|
Less accumulated depreciation
|
|
|
10,007
|
|
|
|
9,140
|
|
|
|
|
$
|
8,915
|
|
|
$
|
8,962
|
|
Other Intangible Assets: Information regarding the Company’s other intangible assets as of April 30, 2014 and July 31, 2013, respectively, were as follows:
|
|
|
Gross Carrying Value
|
|
|
Accumulated Amortization
|
|
|
Net
|
|
|
|
|
April 30, 2014
|
|
|
Proprietary know-how
|
|
$
|
4,057
|
|
|
$
|
2,471
|
|
|
$
|
1,586
|
|
|
Trademark
|
|
|
5,943
|
|
|
|
--
|
|
|
|
5,943
|
|
|
Licensing agreement
|
|
|
5,834
|
|
|
|
2,968
|
|
|
|
2,866
|
|
|
Customer relationships
|
|
|
584
|
|
|
|
46
|
|
|
|
538
|
|
|
Other intangibles
|
|
|
447
|
|
|
|
39
|
|
|
|
408
|
|
|
Patents
|
|
|
2,387
|
|
|
|
919
|
|
|
|
1,468
|
|
|
|
|
$
|
19,252
|
|
|
$
|
6,443
|
|
|
$
|
12,809
|
|
|
|
|
July 31, 2013
|
|
|
Proprietary know-how
|
|
$
|
4,057
|
|
|
$
|
2,286
|
|
|
$
|
1,771
|
|
|
Trademark
|
|
|
5,938
|
|
|
|
--
|
|
|
|
5,938
|
|
|
Licensing agreement
|
|
|
5,834
|
|
|
|
2,766
|
|
|
|
3,068
|
|
|
Customer relationships
|
|
|
531
|
|
|
|
--
|
|
|
|
531
|
|
|
Other intangibles
|
|
|
407
|
|
|
|
--
|
|
|
|
407
|
|
|
Patents
|
|
|
2,270
|
|
|
|
859
|
|
|
|
1,411
|
|
|
|
|
$
|
19,037
|
|
|
$
|
5,911
|
|
|
$
|
13,126
|
|
Goodwill of $1,643,000 and other intangibles of $1,030,000 are a result of the acquisition of M.I.S.S. completed on July 8, 2013. Goodwill of $10,660,000 and proprietary know-how of $4,057,000 are a result of the reverse merger transaction completed on September 21, 2005.
The Company did not incur costs to renew or extend the term of acquired intangible assets during the period ended April 30, 2014. Amortization expense is included in general and administrative expense and was $187,000 and $553,000 for the three and nine months ended April 30, 2014, respectively. Amortization expense for the next five years is expected to approximate $800,000 annually.
Pledged Assets; Short and Long-Term Debt (Excluding Revenue Bonds Payable): Short-term debt as of April 30, 2014 and July 31, 2013, consisted of the following:
Revolving Credit Facility: The Company has a credit facility with a bank which allows for borrowings of up to $9.5 million (collateral available on April 30, 2014 permits borrowings up to $9.5 million) with an interest rate based on either the one-, two- or three-month LIBOR plus 2.0 percent and adjusting each quarter based upon the Company’s leverage ratio. As of April 30, 2014, the interest rate under the facility would have been 2.15 percent. The unused portion of the facility is charged at a rate of 0.20 percent. There were no borrowings under this facility at April 30, 2014. Outstanding amounts are collateralized by the Company’s domestic receivables and inventory. This credit facility was amended on September 30, 2013, to extend the termination date through September 30, 2016.
The facility has two financial covenants: a maximum leverage ratio of 3.75 times and a minimum fixed charge coverage ratio of 1.1 times. As of April 30, 2014, the leverage ratio was 0.56 times and the minimum fixed charge coverage ratio was 3,050 times. The facility restricts the payment of dividends if, following the distribution, the fixed charge coverage ratio would fall below the required minimum.
Equipment Line of Credit: Under this credit facility, the Company may borrow up to $1.0 million, with interest at one-month LIBOR plus 3.0 percent. Pursuant to the terms of the equipment line of credit, under no circumstances shall the rate be less than 3.5 percent per annum. The unused portion of the facility is not charged a fee. There were no borrowings under this facility at April 30, 2014. The equipment line of credit was amended on September 30, 2013, to extend the maturity date to September 30, 2016.
Deferred Revenue: Deferred revenue as of April 30, 2014 and July 31, 2013, respectively, consisted of the following:
|
|
|
April 30, 2014
|
|
|
July 31, 2013
|
|
|
Deferred revenue – Alcon, Inc. settlement
|
|
$
|
14,852
|
|
|
$
|
15,818
|
|
|
Less: Short-term portion
|
|
|
1,288
|
|
|
|
1,288
|
|
|
Long-term portion
|
|
$
|
13,564
|
|
|
$
|
14,530
|
|
Note 9. Commitments and Contingencies
The Company has entered into change of control agreements with each of its President and Chief Executive Officer, Chief Financial Officer, Vice President of Domestic Sales and Vice President of Marketing and Technology. The change of control agreements with its executive officers provide that if employment is terminated within one year for cause or disability following a change in control (as each term is defined in the change in control agreements), as a result of the officer’s death, or by the officer other than as an involuntary termination (as defined in the change in control agreements), the Company shall pay the officer all compensation earned or accrued through his or her employment termination date, including (i) base salary; (ii) reimbursement for reasonable and necessary expenses; (iii) vacation pay; (iv) bonuses and incentive compensation; and (v) all other amounts to which they are entitled under any compensation or benefit plan of the Company (“Standard Compensation Due”).
If the officer’s employment is terminated within one year following a change of control without cause and for any reason other than death or disability, including an involuntary termination, and provided the officer enters into a separation agreement within 30 days of his or her employment termination, he or she shall receive the following: (i) all Standard Compensation Due and any amount payable as of the termination date under the Company’s objectives-based incentive plan, the sum of which shall be paid in a lump sum immediately upon such termination; and (ii) an amount equal to one times his or her annual base salary at the rate in effect immediately prior to the change in control, to be paid in 12 equal monthly installments beginning in the month following his or her employment termination. Furthermore, all of the officer’s awards of shares or options shall immediately vest and be exercisable for one year after the date of his or her employment termination.
Various claims, incidental to the ordinary course of business, are pending against the Company. In the opinion of management, after consultation with legal counsel, resolution of these matters is not expected to have a material effect on the accompanying financial statements.
The Company is subject to regulatory requirements throughout the world. In the normal course of business, regulatory agencies may require companies in the medical industry to change their products or operating procedures, which could affect the Company. The Company regularly incurs expenses to comply with these regulations and may be required to incur additional expenses. Management is not able to estimate any additional expenditures outside the normal course of operations which will be incurred by the Company in future periods in order to comply with these regulations.
Note 10. Enterprise-wide Sales Information
Enterprise-wide sales information for the three and nine months ended April 30, 2014 and 2013, respectively, consisted of the following:
|
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Net Sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ophthalmic
|
|
$
|
8,494
|
|
|
$
|
8,666
|
|
|
$
|
25,730
|
|
|
$
|
26,012
|
|
|
OEM (1)
|
|
|
7,383
|
|
|
|
7,388
|
|
|
|
20,355
|
|
|
|
18,314
|
|
|
Other (2)
|
|
|
258
|
|
|
|
210
|
|
|
|
676
|
|
|
|
613
|
|
|
Total
|
|
$
|
16,135
|
|
|
$
|
16,264
|
|
|
$
|
46,761
|
|
|
$
|
44,939
|
|
|
Net Sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic
|
|
$
|
12,106
|
|
|
$
|
12,345
|
|
|
$
|
35,025
|
|
|
$
|
33,154
|
|
|
International
|
|
|
4,029
|
|
|
|
3,919
|
|
|
|
11,736
|
|
|
|
11,785
|
|
|
|
|
$
|
16,135
|
|
|
$
|
16,264
|
|
|
$
|
46,761
|
|
|
$
|
44,939
|
|
|
(1) |
Net sales to OEM customers represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel ablation generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius Therapeutics LLC. In addition, deferred revenues of $322,000 and $966,000 from the 2010 settlement with Alcon, Inc. (the “2010 Alcon settlement”) are included in this category for the three and nine months ended April 30, 2014 and 2013, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact the Company’s future liquidity. |
|
(2) |
Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues. |
Note 11. Recent Accounting Pronouncements
In March 2013, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update requiring an entity to release into net income the entire amount of a cumulative translation adjustment related to its investment in a foreign entity when as a parent it either sells a part or all of its investment in the foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets within the foreign entity. This accounting standard update will be effective for the Company beginning in the first quarter of fiscal 2015. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.
In July 2013, the FASB issued an accounting standard update that provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward or a tax credit carryforward exists. Under the new standard update, unrecognized tax benefit, or a portion of an unrecognized tax benefit, is to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward or a tax credit carryforward. This accounting standard update will be effective for the Company beginning in the first quarter fiscal 2015 and applied prospectively with early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.
In April 2014, the FASB issued an accounting standard update increasing the threshold for a disposal to qualify as a discontinued operation and require new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. The standard will be effective for the Company beginning in the second quarter fiscal 2015. The adoption of the pronouncement may affect the Company’s presentation of future dispositions.
In May 2014, the FASB issued an accounting standard update that provides explicit guidance on the recognition of revenue based upon the entity’s contracts with customers to transfer goods or services. Under the new standard update, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This accounting standard update will be effective for the Company in the first quarter of fiscal 2018. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.
The Company has reviewed all other recently issued, but not yet effective, accounting pronouncements and does not believe any such pronouncements will have a material impact on its financial statements.
Item 2 —
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
Synergetics USA, Inc. (“Synergetics USA” or the “Company”) is a leading supplier of precision surgical devices. The Company’s primary focus is on the surgical disciplines of ophthalmology and neurosurgery. Our distribution channels include a combination of direct and independent vitreoretinal sales organizations, both domestically and internationally, and important strategic alliances with market leaders. The Company’s product lines focus upon precision engineered, disposable and reusable devices, surgical equipment, procedural kits and the delivery of various energy modalities for the performance of surgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency energy for electrosurgery and lesion generation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. Enterprise-wide sales information is included in Note 10 to the unaudited condensed consolidated financial statements.
The Company is a Delaware corporation incorporated on June 2, 2005 in connection with the reverse merger of Synergetics, Inc. (“Synergetics”) and Valley Forge Scientific Corp. (“Valley Forge”) and the subsequent reincorporation of Valley Forge (the predecessor to Synergetics USA) in Delaware. Synergetics was founded in 1991. Valley Forge was incorporated in 1980 and became a publicly-held company in November 1989. The Company’s securities are listed on The NASDAQ Capital Market under the ticker symbol “SURG.”
Recent Developments
Over the past few years, we have had several developments that we expect will contribute to the growth of our business in the foreseeable future, the most recent of which are as follows:
|
· |
On June 27, 2012, the Company announced that it received 510(k) clearance from the U.S. Food and Drug Administration for VersaVITTM, a novel vitrectomy system for the retinal surgery market. On July 20, 2012, the VersaVITTM vitrectomy system received clearance for the “CE” mark, allowing access to the European market. The Company continues its commercialization efforts on VersaVITTM and its related consumables. |
|
· |
On November 28, 2012, the Company announced the signing of the third amendment to its agreement with Stryker Corporation (“Stryker”) for supply and distribution of a lesion generator and accessories, extending the expiration date until June 30, 2015. |
|
· |
On July 9, 2013, the Company announced that it had acquired M.I.S.S. Ophthalmics Limited (“M.I.S.S.”), a private ophthalmology distribution company incorporated in England and Wales, for net cash consideration of $2.8 million. M.I.S.S. was our distributor of ophthalmic products in the United Kingdom, and its wholesale distribution activities contributed approximately $1.1 million in revenue to the Company in fiscal 2013. M.I.S.S. generated total revenue of approximately $3.2 million during its fiscal year ended March 31, 2013 and was solidly profitable on an operating basis. The acquisition establishes a direct presence in one of the largest ophthalmic markets outside the U.S., which we believe will drive future operating efficiencies throughout our European operations, enhance sales management capabilities and favorably impact both top and bottom line financial performance in fiscal 2014. |
|
· |
On September 30, 2013, the Company extended its revolving credit facility and its equipment line of credit through September 30, 2016. |
|
· |
On October 1, 2013, the Company announced plans to close its King of Prussia, Pennsylvania facility and consolidate the manufacturing operations into its existing facility in O’Fallon, Missouri. The Company expects to expense approximately $1.2 million, of which $578,000 was expended during the first nine months of fiscal 2014. The remaining $586,000 will be expended over the next eight months to complete the closure. The Company expects the closure to result in a reduction in operating expense of more than $1.1 million on an annualized basis beginning in fiscal 2016. |
|
· |
On May 5, 2014, the Company announced the launch of the next generation DirectionalTM Laser Probe. The DirectionalTM II Laser Probe is a significant improvement on the original DirectionalTM Laser Probe as it incorporates years of feedback from the original design. The improvements include an ergonomic, color-coded handle that emulates the PinnacleTM instrument line. In addition, it incorporates significant improvements on the mechanism responsible for adjusting the fiber from straight to curved. |
|
· |
On May 12, 2014, the Company announced the completion of a cooperative development agreement with Cleveland Clinic to develop the next generation of intraoperative devices. These devices are expected to lead to improved visualization of surgical sites leading to more precise tissue targeting and improved surgical outcomes. |
|
· |
On June 9, 2014, the Company announced the targeted launch of the next generation vitrectomy system, VersaVIT 2.0TM, in the second-half of June. VersaVIT 2.0TM offers an improvement over the first generation system by providing high speed cutting in combination with active duty cycle control. Combined, both high speed cutting and duty cycle control provide surgeons with a more efficient way to remove vitreous while simultaneously increasing safety by decreasing traction on retinal tissues when shaving along the base of the retina. Additional features of the VersaVIT 2.0™ system and accessories include LED illumination, pressurized infusion and a silicone oil collection chamber.
|
Summary of Financial Information
The following tables present net sales by category and our results of operations (dollars in thousands):
NET SALES BY CATEGORY
|
|
|
Three Months Ended April 30, 2014
|
|
|
Mix
|
|
|
Three Months Ended April 30, 2013
|
|
|
Mix
|
|
|
Ophthalmic
|
|
$
|
8,494
|
|
|
|
52.6
|
%
|
|
$
|
8,666
|
|
|
|
53.3
|
%
|
|
OEM (1)
|
|
|
7,383
|
|
|
|
45.8
|
%
|
|
|
7,388
|
|
|
|
45.4
|
%
|
|
Other (2)
|
|
|
258
|
|
|
|
1.6
|
%
|
|
|
210
|
|
|
|
1.3
|
%
|
|
Total
|
|
$
|
16,135
|
|
|
|
|
|
|
$
|
16,264
|
|
|
|
|
|
|
|
|
Nine Months Ended April 30, 2014
|
|
|
Mix
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Mix
|
|
|
Ophthalmic
|
|
$
|
25,730
|
|
|
|
55.0
|
%
|
|
$
|
26,012
|
|
|
|
57.9
|
%
|
|
OEM (1)
|
|
|
20,355
|
|
|
|
43.5
|
%
|
|
|
18,314
|
|
|
|
40.7
|
%
|
|
Other (2)
|
|
|
676
|
|
|
|
1.5
|
%
|
|
|
613
|
|
|
|
1.4
|
%
|
|
Total
|
|
$
|
46,761
|
|
|
|
|
|
|
$
|
44,939
|
|
|
|
|
|
|
(1) |
Net sales to OEM customers represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman & Shurtleff, Inc. (“Codman”), multi-channel ablation generators, disposable ultrasonic aspirator tips and related accessories to Stryker and sales of certain disposable products to Mobius Therapeutics LLC (“Mobius”). In addition, deferred revenues of $322,000 and $966,000 from the 2010 settlement with Alcon, Inc. (“Alcon”) are included in this category for the three and nine months ended April 30, 2014 and 2013, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact our future liquidity. |
|
(2) |
Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues. |
The decrease in sales for the third quarter of fiscal 2014 compared with the third quarter of fiscal 2013 was primarily due to the decrease of $172,000 in ophthalmic sales. In the third quarter of fiscal 2014, disposable product sales account for approximately 85.9 percent of our total product sales. Overall sales of our disposable products grew $869,000, or 6.7 percent, in the third quarter of fiscal 2014 as compared to the comparable period of fiscal 2013. Sales of capital equipment decreased by approximately $998,000, or 33.9 percent, in the third quarter of fiscal 2014 as compared to the comparable period of fiscal 2013.
RESULTS OF OPERATIONS
(Dollars in thousands, except for per share amounts)
|
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Increase (Decrease)
|
|
|
Net Sales
|
|
$
|
16,135
|
|
|
$
|
16,264
|
|
|
|
(0.8
|
%)
|
|
Gross Profit
|
|
|
8,912
|
|
|
|
9,051
|
|
|
|
(1.5
|
%)
|
|
Gross Profit Margin %
|
|
|
55.2
|
%
|
|
|
55.7
|
%
|
|
(50 bps
|
) |
|
Commercial Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and Development
|
|
|
1,302
|
|
|
|
973
|
|
|
|
33.8
|
%
|
|
Sales and Marketing
|
|
|
3,450
|
|
|
|
3,523
|
|
|
|
(2.1
|
%)
|
|
General and Administrative
|
|
|
2,602
|
|
|
|
2,719
|
|
|
|
(4.3
|
%)
|
|
Exit costs
|
|
|
64
|
|
|
|
--
|
|
|
|
N/M
|
(1)
|
|
Medical Device Excise Tax
|
|
|
83
|
|
|
|
115
|
|
|
|
(27.8
|
%)
|
|
Operating Income
|
|
|
1,411
|
|
|
|
1,721
|
|
|
|
(18.0
|
%)
|
|
Operating Margin
|
|
|
8.7
|
%
|
|
|
10.6
|
%
|
|
(190 bps
|
) |
|
EBITDA (2)
|
|
|
1,892
|
|
|
|
2,215
|
|
|
|
(14.6
|
%)
|
|
Net Income
|
|
|
943
|
|
|
|
1,150
|
|
|
|
(18.0
|
%)
|
|
Earnings per share
|
|
$
|
0.04
|
|
|
$
|
0.05
|
|
|
|
(20.0
|
%)
|
|
Return on average equity (2)
|
|
|
1.5
|
%
|
|
|
2.0
|
%
|
|
(50 bps
|
) |
|
Return on average assets (2)
|
|
|
1.1
|
%
|
|
|
1.5
|
%
|
|
(40 bps
|
) |
|
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Increase (Decrease)
|
|
|
Net Sales
|
|
$
|
46,761
|
|
|
$
|
44,939
|
|
|
|
4.1
|
%
|
|
Gross Profit
|
|
|
26,234
|
|
|
|
22,695
|
|
|
|
15.6
|
%
|
|
Gross Profit Margin %
|
|
|
56.1
|
%
|
|
|
50.5
|
%
|
|
560 bps
|
|
|
Commercial Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and Development
|
|
|
4,012
|
|
|
|
2,660
|
|
|
|
50.8
|
%
|
|
Sales and Marketing
|
|
|
10,655
|
|
|
|
10,367
|
|
|
|
2.8
|
%
|
|
General and Administrative
|
|
|
8,240
|
|
|
|
7,999
|
|
|
|
3.0
|
%
|
|
Exit costs
|
|
|
578
|
|
|
|
--
|
|
|
|
N/M
|
(1)
|
|
Medical Device Excise Tax
|
|
|
323
|
|
|
|
160
|
|
|
|
101.9
|
%
|
|
Operating Income
|
|
|
2,426
|
|
|
|
1,509
|
|
|
|
60.8
|
%
|
|
Operating Margin
|
|
|
5.2
|
%
|
|
|
3.4
|
%
|
|
180 bps
|
|
|
EBITDA (2)
|
|
|
3,850
|
|
|
|
2,852
|
|
|
|
35.0
|
%
|
|
Net Income
|
|
|
1,652
|
|
|
|
1,120
|
|
|
|
47.5
|
%
|
|
Earnings per share
|
|
$
|
0.07
|
|
|
$
|
0.04
|
|
|
|
75.0
|
%
|
|
Return on average equity (2)
|
|
|
2.7
|
%
|
|
|
1.9
|
%
|
|
80 bps
|
|
|
Return on average assets (2)
|
|
|
2.0
|
%
|
|
|
1.4
|
%
|
|
60 bps
|
|
|
(2) |
EBITDA, return on average equity and return on average assets are not financial measures recognized by U.S. generally accepted accounting principles (“GAAP”). EBITDA is defined as income from operations before interest expense, income taxes, depreciation and amortization. Return on average equity is defined as net income divided by average equity. Return on average assets is defined as net income plus interest expense divided by average assets. See disclosure following regarding the use of non-GAAP financial measures. |
Reconciliation of Non-GAAP Financial Measures (dollars in thousands)
|
EBITDA Reconciliation
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Net income
|
|
$
|
943
|
|
|
$
|
1,150
|
|
|
Interest expense
|
|
|
--
|
|
|
|
2
|
|
|
Income taxes
|
|
|
469
|
|
|
|
562
|
|
|
Depreciation
|
|
|
293
|
|
|
|
314
|
|
|
Amortization
|
|
|
187
|
|
|
|
187
|
|
|
EBITDA
|
|
$
|
1,892
|
|
|
$
|
2,215
|
|
|
EBITDA Reconciliation
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Net income
|
|
$
|
1,652
|
|
|
$
|
1,120
|
|
|
Interest expense
|
|
|
--
|
|
|
|
6
|
|
|
Income taxes
|
|
|
781
|
|
|
|
366
|
|
|
Depreciation
|
|
|
864
|
|
|
|
856
|
|
|
Amortization
|
|
|
553
|
|
|
|
504
|
|
|
EBITDA
|
|
$
|
3,850
|
|
|
$
|
2,852
|
|
|
Return on Average Equity Calculation
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Net income
|
|
$
|
943
|
|
|
$
|
1,150
|
|
|
Average Equity
|
|
|
|
|
|
|
|
|
|
April 30, 2014
|
|
|
62,853
|
|
|
|
|
|
|
January 31, 2014
|
|
|
61,667
|
|
|
|
|
|
|
April 30, 2013
|
|
|
|
|
|
|
58,463
|
|
|
January 31, 2013
|
|
|
|
|
|
|
57,317
|
|
|
Average Equity
|
|
|
62,260
|
|
|
|
57,890
|
|
|
Return on Average Equity
|
|
|
1.5
|
%
|
|
|
2.0
|
%
|
|
Return on Average Equity Calculation
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Net income
|
|
$
|
1,652
|
|
|
$
|
1,120
|
|
|
Average Equity
|
|
|
|
|
|
|
|
|
|
April 30, 2014
|
|
|
62,853
|
|
|
|
|
|
|
January 31, 2014
|
|
|
61,667
|
|
|
|
|
|
|
October 31, 2013
|
|
|
61,445
|
|
|
|
|
|
|
July 31, 2013
|
|
|
60,152
|
|
|
|
|
|
|
April 30, 2013
|
|
|
|
|
|
|
58,463
|
|
|
January 31, 2013
|
|
|
|
|
|
|
57,317
|
|
|
October 31, 2012
|
|
|
|
|
|
|
58,143
|
|
|
July 31, 2012
|
|
|
|
|
|
|
56,478
|
|
|
Average Equity
|
|
|
61,529
|
|
|
|
57,600
|
|
|
Return on Average Equity
|
|
|
2.7
|
%
|
|
|
1.9
|
%
|
|
Return on Average Assets Calculation
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Net income
|
|
$
|
943
|
|
|
$
|
1,150
|
|
|
Interest expense
|
|
|
--
|
|
|
|
2
|
|
|
Net Income + Interest expense
|
|
$
|
943
|
|
|
$
|
1,152
|
|
|
Average Assets
|
|
|
|
|
|
|
|
|
|
April 30, 2014
|
|
|
83,843
|
|
|
|
|
|
|
January 31, 2014
|
|
|
82,389
|
|
|
|
|
|
|
April 30, 2013
|
|
|
|
|
|
|
79,763
|
|
|
January 31, 2013
|
|
|
|
|
|
|
78,151
|
|
|
Average Assets
|
|
|
83,116
|
|
|
|
78,957
|
|
|
Return on Average Assets
|
|
|
1.1
|
%
|
|
|
1.5
|
%
|
|
Return on Average Assets Calculation
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Net income
|
|
$
|
1,652
|
|
|
$
|
1,120
|
|
|
Interest Expense
|
|
|
--
|
|
|
|
6
|
|
|
Net Income + Interest Expense
|
|
$
|
1,652
|
|
|
$
|
1,126
|
|
|
Average Assets
|
|
|
|
|
|
|
|
|
|
April 30, 2014
|
|
|
83,843
|
|
|
|
|
|
|
January 31, 2014
|
|
|
82,389
|
|
|
|
|
|
|
October 31, 2013
|
|
|
83,334
|
|
|
|
|
|
|
July 31, 2013
|
|
|
82,693
|
|
|
|
|
|
|
April 30, 2013
|
|
|
|
|
|
|
79,763
|
|
|
January 31, 2013
|
|
|
|
|
|
|
78,151
|
|
|
October 31, 2012
|
|
|
|
|
|
|
80,156
|
|
|
July 31, 2012
|
|
|
|
|
|
|
78,763
|
|
|
Average Assets
|
|
|
83,065
|
|
|
|
79,208
|
|
|
Return on Average Assets
|
|
|
2.0
|
%
|
|
|
1.4
|
%
|
We measure our performance primarily through our revenue and operating profit growth. In addition to our consolidated financial statements presented in accordance with GAAP, management uses certain non-GAAP measures, including EBITDA, return on average equity and return on average assets, to measure our operating performance. We provide a definition of the components of these measurements and reconciliation to the most directly comparable GAAP financial measure.
These non-GAAP measures are presented to enhance an understanding of our operating results and are not intended to represent cash flow or results of operations. The use of these non-GAAP measures provides an indication of our ability to service debt and measure operating performance. We believe these non-GAAP measures are useful in evaluating our operating performance compared to other companies in our industry, and are beneficial to investors, potential investors and other key stakeholders, including creditors who use this measure in their evaluation of performance.
These non-GAAP measures are not in accordance with, or an alternative to, measures prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP. These measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures.
Results Overview
Product categories as a percentage of total sales were as follows:
|
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Ophthalmic
|
|
|
52.6
|
%
|
|
|
53.3
|
%
|
|
|
55.0
|
%
|
|
|
57.9
|
%
|
|
OEM
|
|
|
45.8
|
%
|
|
|
45.4
|
%
|
|
|
43.5
|
%
|
|
|
40.7
|
%
|
|
Other
|
|
|
1.6
|
%
|
|
|
1.3
|
%
|
|
|
1.5
|
%
|
|
|
1.4
|
%
|
|
Total
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
100.00
|
%
|
International revenues represent $4.0 million, or 25.0 percent, of our total revenues for the three months ended April 30, 2014, as compared to $3.9 million, or 24.1 percent, for the three months ended April 30, 2013. International revenues represent $11.7 million, or 25.1 percent, of our total revenues for the nine months ended April 30, 2014, as compared to $11.8 million, or 26.2 percent, for the nine months ended April 30, 2013. Many of the products we sell to our OEM customers in the U.S. are subsequently shipped to their non-U.S. customers in various countries around the world, but revenue attributable to these sales is included in our domestic revenues.
Our Business Strategy
The Company’s strategy is to enhance shareholder value through profitable revenue growth in targeted segments of the ophthalmology and neurosurgery markets. This is accomplished through the identification and development of reusable and disposable devices in collaboration with leading surgeons and OEM partners. We are committed to establishing a strong operational infrastructure and financial foundation within which growth opportunities can be prudently evaluated, financed and pursued. We will remain vigilant and sensitive to new challenges which may arise from changes in the definition and delivery of appropriate healthcare in our fields of interest. In fiscal 2014 and beyond, our strategic priorities are to generate growth in the ophthalmology business, deliver improved profitability through our enterprise-wide lean initiatives, manage our neurosurgery and other OEM businesses for stable growth and strong cash flows and demonstrate consistent, solid financial performance.
Generate Growth in our Ophthalmology Business
We are focused on expanding our product platform into larger and faster-growing segments of the vitreoretinal device market. Thus, we have focused our internal research and development efforts on developing innovative technologies that will enable the Company to enhance its value to the vitreoretinal community. We are implementing several focused initiatives to capitalize on our recent new product introduction, the VersaVITTM, and other new products, and capitalize on the current macroeconomic environment. In addition, we are also seeking business development opportunities to augment and complement our existing ophthalmic franchise. Finally, we are improving our sales force productivity. For example, in the U.S., we are focused on enhancing our compensation programs to target the appropriate mix of product and rigorous development of our sales force capabilities through enhanced training and customer relationship management. Additionally, in the international markets, we are working to optimize our sales capabilities and distribution infrastructure. Our recent acquisition of M.I.S.S. demonstrates our commitment to enhancing our international distribution infrastructure.
Deliver Improved Profitability through our Enterprise-Wide Lean Initiatives
We have been developing comprehensive enterprise-wide initiatives aimed at creating a more efficient operating platform. The lean mindset has permeated our corporate culture. We believe we have taken over $3.0 million out of our cost basis since we implemented our lean efforts. In addition, we implemented our Enterprise Resource Planning (“ERP”) system in August 2011. Continued improvements throughout the organization are expected to emerge as we optimize the ERP system.
On October 1, 2013, the Company announced plans to close its King of Prussia, Pennsylvania facility and consolidate the manufacturing operations into its existing facility in O’Fallon, Missouri. The Company expects to expense approximately $1.2 million, of which $578,000 was expended during the first nine months of fiscal 2014. The remaining $586,000 will be expended over the next eight months to complete the closure. The Company expects the closure to result in a reduction in operating expense of more than $1.1 million on an annualized basis beginning in fiscal 2016.
Manage our Neurosurgery and OEM Businesses for Stable Growth and Strong Cash Flows
We produce most of our OEM produce under contracts established with our two largest OEM partners, Codman and Stryker. These relationships provide high visibility within the neurosurgery and pain control markets. We provide best-in-class technologies with our electrosurgery generators and disposable bipolar forceps being distributed by Codman and our multi-channel ablation generator and ultrasonic aspirator disposables being distributed by Stryker. We are working with both of these OEM partners to provide product line iterations to maintain their technological advantages. We also work to develop relationships with a select number of other potential OEM customers which would continue to enhance our OEM platform growth and profitability to complement our strategic focus.
Demonstrate Consistent, Solid Financial Performance
In the short and long-term, we continue to expect to deliver a growing revenue stream and meet increasing earnings objectives. We also will enhance our working capital usage by employing both our lean philosophy and our ERP system to derive more cash flow from the business. We will prudently manage our capital structure to allow for additional growth opportunities and optimal cash deployment.
Trends
Demand Trends
The Company’s sales increased 4.1 percent during the first nine months of fiscal 2014, compared with the first nine months of fiscal 2013. The most significant factor impacting this increase was an increase of $2.0 million in OEM sales during the first nine months of fiscal 2014 (including $966,000 deferred revenue from the 2010 Alcon settlement in the first nine months of fiscal 2014 and 2013, respectively). In the first nine months of fiscal 2014, disposable product sales accounted for approximately 87.2 percent of our total product sales. Overall sales of our disposable products grew $4.3 million, or 11.7 percent, in the first nine months of fiscal 2014, as compared to the comparable period of fiscal 2013. Sales of capital equipment decreased by approximately $2.3 million, or 31.5 percent, in the first nine months of fiscal 2014, as compared to the comparable period of fiscal 2013.
Based upon a study performed by Market Scope LLC (“Market Scope”), dated March 2012, there are approximately 2,000 practicing retinal specialists in the United States and an additional 7,600 throughout the rest of the world. In 2013, Market Scope estimated that approximately 324,000 vitrectomies would be performed in the United States and 1.26 million total vitrectomies would be performed throughout the world. Market Scope estimates that these procedures are growing at a rate of 2.4 percent annually.
Neurosurgical procedures on a global basis continue to rise at an estimated 1 to 3 percent growth rate, driven by an aging global population, new technologies, advances in surgical techniques and a growing global market resulting from ongoing improvements in healthcare delivery in emerging markets, among other factors. Based upon this growth in procedures, sales of neurosurgical products worldwide are forecasted to increase by approximately 4 percent.
In addition, we believe that the demand for high quality, innovative products and new technologies consistent with the Company’s devices and disposables will continue to favorably impact procedure growth in the ophthalmic and neurosurgical markets.
Pricing Trends
Due to the development and launch of new products, the Company has observed significant discounting practices from some of our major competitors in an effort to preserve their market share. This, combined with an increase in product commoditization in the retinal space, is increasing the pricing pressures on our ophthalmic products. The Company has no major domestic group purchasing agreements.
Economic Trends
Economic conditions may continue to negatively impact capital expenditures at the hospital, ambulatory surgical center and physician level. Further, global economic conditions continue to negatively impact the volume and average selling price of the Company’s products in our European markets. The Company’s international sales of ophthalmic products decreased 0.6 percent during the nine months ended April 30, 2014, as compared to the nine months ended April 30, 2013.
Results of Operations
Three-Month Period Ended April 30, 2014, Compared to Three-Month Period Ended April 30, 2013
Results Overview
During the third quarter ended April 30, 2014, the Company recorded net sales of $16.1 million, which generated $8.9 million in gross profit, operating income of $1.4 million and net income of approximately $943,000, or $0.04 income per share. The Company had $12.8 million in cash and no interest-bearing debt as of April 30, 2014. Management believes that cash flows from operations, together with available cash, will be sufficient to meet the Company’s working capital and capital expenditure needs for the next 12 months.
Net Sales
The following table presents net sales by category (dollars in thousands):
|
|
|
Three Months Ended
April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Increase (Decrease)
|
|
|
Ophthalmic
|
|
$
|
8,494
|
|
|
$
|
8,666
|
|
|
|
(2.0
|
%)
|
|
OEM (1)
|
|
|
7,383
|
|
|
|
7,388
|
|
|
|
(0.1
|
%)
|
|
Other (2)
|
|
|
258
|
|
|
|
210
|
|
|
|
22.9
|
%
|
|
Total
|
|
$
|
16,135
|
|
|
$
|
16,264
|
|
|
|
(0.8
|
%)
|
|
(1) |
Net sales to OEM customers represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel ablation generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius. In addition, deferred revenues of $322,000 from the 2010 settlement with Alcon are included in this category for the three months ended April 30, 2014 and 2013, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact our future liquidity. |
|
(2) |
Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues. |
Ophthalmic sales decreased 2.0 percent in the third quarter of fiscal 2014, compared to the third quarter of fiscal 2013. Domestic ophthalmic sales decreased 6.1 percent in the third quarter of fiscal 2014, primarily due to the decreased sales of base business capital equipment and disposables, partially offset by increased sales of procedural kits (including kits associated with VersaVITTM). International ophthalmic sales increased 3.1 percent in the third quarter of fiscal 2014, primarily due to sales from M.I.S.S. and positive currency exchange, partially offset by decreased sales of base business capital equipment and disposables. OEM sales decreased $5,000 in the third quarter of fiscal 2014 as compared to the third quarter of fiscal 2013. Total OEM sales decreased 0.1 percent to $7.4 million in the third quarter of fiscal 2014 (including $322,000 of deferred revenue recognized from the 2010 Alcon settlement), compared with $7.4 million in the third quarter of fiscal 2013 (including $322,000 of deferred revenue recognized). OEM sales benefited from strong volumes of disposable products sold to Codman and Stryker, offset by decreased electrosurgery generator sales to Codman. Other sales increased $48,000 in the third quarter of fiscal 2014, or 22.9 percent, compared to the third quarter of fiscal 2013.
In the third quarter of fiscal 2014, disposable product sales accounted for approximately 85.9 percent of our total product sales. Overall sales of our disposable products grew $869,000, or 6.7 percent, in the third quarter of fiscal 2014, as compared to the comparable period of fiscal 2013. Sales of capital equipment decreased by approximately $998,000, or 33.9 percent, in the third quarter of fiscal 2014 as compared to the comparable period of fiscal 2013.
The following table presents domestic and international net sales (dollars in thousands):
|
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
Increase (Decrease)
|
|
|
Domestic (including Marketing Partners and OEM sales)
|
|
$
|
12,106
|
|
|
$
|
12,345
|
|
|
|
(1.9
|
%)
|
|
International (including Canada)
|
|
|
4,029
|
|
|
|
3,919
|
|
|
|
2.8
|
%
|
|
Total
|
|
$
|
16,135
|
|
|
$
|
16,264
|
|
|
|
(0.8
|
%)
|
Domestic sales decreased 1.9 percent in the third quarter of fiscal 2014 due to decreases in ophthalmic and OEM sales which are recorded as domestic sales. International sales increased 2.8 percent in the third quarter of fiscal 2014 primarily due to the increase in international ophthalmology sales of 3.1 percent. The increase in international ophthalmology sales was primarily due to sales from M.I.S.S. and positive currency exchange, partially offset by decreased sales of ophthalmic base business capital equipment and disposables.
Gross Profit
Gross profit as a percentage of net sales was 55.2 percent in the third quarter of fiscal 2014 compared to 55.7 percent for the same period in fiscal 2013. Gross profit as a percentage of net sales for the third quarter of fiscal 2014 compared to the third quarter of fiscal 2013 decreased 0.5 percentage points. Gross profit margin for the third quarter of fiscal 2014 was negatively impacted by the mix of products including both the increase in our international sales and the increase in the percentage of our OEM sales.
Operating Expenses (dollars in thousands)
|
|
|
Three Months Ended April 30, 2014
|
|
|
Three Months Ended April 30, 2013
|
|
|
|
|
Dollars
|
|
|
Percent of Sales
|
|
|
Dollars
|
|
|
Percent of Sales
|
|
|
Research & Development Expenses
|
|
$
|
1,302
|
|
|
|
8.1
|
%
|
|
$
|
973
|
|
|
|
6.0
|
%
|
|
Sales & Marketing Expenses
|
|
|
3,450
|
|
|
|
21.4
|
%
|
|
|
3,523
|
|
|
|
21.7
|
%
|
|
General & Administrative Expenses
|
|
|
2,602
|
|
|
|
16.1
|
%
|
|
|
2,719
|
|
|
|
16.7
|
%
|
|
Exit Costs
|
|
|
64
|
|
|
|
0.4
|
%
|
|
|
--
|
|
|
|
--
|
%
|
|
Medical Device Excise Tax
|
|
|
83
|
|
|
|
0.5
|
%
|
|
|
115
|
|
|
|
0.7
|
%
|
Research and development expenses (“R&D”) as a percentage of net sales was 8.1 percent and 6.0 percent for the third quarter of fiscal 2014 and 2013, respectively. R&D investment increased $329,000 in the third quarter of fiscal 2014 compared to the same period in fiscal 2013. The Company’s pipeline included approximately 26 active projects in various stages of completion as of April 30, 2014. The Company’s R&D investment is driven by the opportunities to accelerate new products to meet the needs of its surgeon customers and address the demands of the market. This results in an investment rate that the Company believes is comparable to such spending by other medical device companies. The Company expects to invest in R&D at a rate of approximately 6.0 to 8.0 percent of net sales over the next few years.
Sales and marketing expenses decreased $73,000 to approximately $3.4 million, or 21.4 percent of net sales, for the third quarter of fiscal 2014 compared to $3.5 million, or 21.7 percent of net sales, for the third quarter of fiscal 2013. The decrease is primarily due to the decrease in domestic ophthalmology sales.
General and administrative expenses decreased by approximately $117,000 to $2.6 million, or 16.1 percent of net sales, in the third quarter of fiscal 2014 compared to $2.7 million, or 16.7 percent of net sales, for the third quarter of fiscal 2013. The decrease is primarily due to the elimination of the Chief Scientific Officer position.
Exit costs were $64,000, or 0.4 percent for net sales, for the third quarter of fiscal 2014 due to the closure of the King of Prussia location. Exit costs consisted primarily of the severance obligations to former employees of this location.
Medical device excise tax was $83,000, or 0.5 percent of net sales, for the third quarter of fiscal 2014 compared to $115,000, or 0.7% of net sales, for the third quarter of fiscal 2013.
Other Income/(Expenses)
Other income for the third quarter of fiscal 2014 was $1,000 as compared to other expense of $9,000 for the third quarter of fiscal 2013.
Operating Income, Income Taxes and Net Income
Operating income for the third quarter of fiscal 2014 decreased $310,000 to $1.4 million, as compared to the comparable 2013 fiscal period. The decrease in the operating income was primarily the result of a 0.8 percent decrease in sales and a 0.1 percent increase in cost of sales, resulting in a $139,000 decrease in gross profit. A 33.8 percent increase in R&D expenses and $64,000 in exit costs associated with the closure of the Company’s King of Prussia location reduced operating income. However, a 2.1 percent decrease in sales and marketing expenses, a 4.3 percent decrease in general and administrative expenses and a 27.8 percent decrease in medical device excise taxes partially offset this decline.
The Company recorded a $469,000 tax provision on pre-tax income of $1.4 million, a 33.2 percent tax provision, in the quarter ended April 30, 2014. In the quarter ended April 30, 2013, the Company recorded a $562,000 tax provision on pre-tax income of $1.7 million, a 32.8 percent tax provision.
Net income decreased by $207,000 to $943,000 for the third quarter of fiscal 2014 from $1.2 million for the same period in fiscal 2013. The decrease in net income was primarily from the decrease in operating income discussed above. Basic and diluted earnings per share for the third quarter of fiscal 2014 was $0.04 as compared to $0.05 in the third quarter of fiscal 2013. Basic weighted average shares outstanding increased from 25,299,131 at April 30, 2013, to 25,331,925 at April 30, 2014.
Nine-Month Period Ended April 30, 2014, Compared to Nine-Month Period Ended April 30, 2013
Net Sales
The following table presents net sales by category (dollars in thousands):
|
|
|
Nine Months Ended
April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Increase
(Decrease)
|
|
|
Ophthalmic
|
|
$
|
25,730
|
|
|
$
|
26,012
|
|
|
|
(1.1
|
%)
|
|
OEM (1)
|
|
|
20,355
|
|
|
|
18,314
|
|
|
|
11.1
|
%
|
|
Other (2)
|
|
|
676
|
|
|
|
613
|
|
|
|
10.3
|
%
|
|
Total
|
|
$
|
46,761
|
|
|
$
|
44,939
|
|
|
|
4.1
|
%
|
|
(1) |
Net sales to OEM customers represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel ablation generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius. In addition, deferred revenues of $966,000 from the 2010 settlement with Alcon are included in this category for the nine months ended April 30, 2014 and 2013, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact our future liquidity. |
|
(2) |
Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues. |
Ophthalmic sales decreased 1.1 percent in the first nine months of fiscal 2014, compared to the first nine months of fiscal 2013. Domestic ophthalmic sales decreased 1.5 percent in the first nine months of fiscal 2014, primarily due to the decreased sales of base business capital equipment and disposables, partially offset by increased sales of procedural kits (including kits associated with VersaVITTM). International ophthalmic sales decreased 0.6 percent in the first nine months of fiscal 2014, primarily due to decreased sales of base business capital equipment and disposables, partially offset by increased sales from M.I.S.S. OEM sales increased $2.0 million in the first nine months of fiscal 2014 as compared to the first nine months of fiscal 2013. Total OEM sales grew 11.1 percent to $20.4 million in the first nine months of fiscal 2014 (including $966,000 of deferred revenue recognized from the 2010 Alcon settlement), compared with $18.3 million in the first nine months of fiscal 2013 (including $966,000 of deferred revenue recognized). The increase in OEM sales benefited from increased volumes of disposable products sold to Codman and Stryker, partially offset by weaker generator sales to Codman and Stryker. Other sales increased $63,000 in the first nine months of fiscal 2014, or 10.3 percent, compared to the first nine months of fiscal 2013.
In the first nine months of fiscal 2014, disposable product sales account for approximately 87.2 percent of our total product sales. Overall sales of our disposable products grew $4.3 million, or 11.7 percent, in the first nine months of fiscal 2014, as compared to the comparable period of fiscal 2013. Sales of capital equipment decreased by approximately $2.3 million, or 31.5 percent, in the first nine months of fiscal 2014 as compared to the comparable period of fiscal 2013.
The following table presents domestic and international net sales (dollars in thousands):
|
|
|
Nine Months Ended April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
Increase (Decrease)
|
|
|
Domestic (including Marketing Partners and OEM sales)
|
|
$
|
35,025
|
|
|
$
|
33,154
|
|
|
|
5.6
|
%
|
|
International (including Canada)
|
|
|
11,736
|
|
|
|
11,785
|
|
|
|
(0.4
|
%)
|
|
Total
|
|
$
|
46,761
|
|
|
$
|
44,939
|
|
|
|
4.1
|
%
|
Domestic sales increased 5.6 percent in the first nine months of fiscal 2014 due primarily to increases in OEM sales which are recorded as domestic sales. International sales decreased 0.4 percent in the first nine months of fiscal 2014 primarily due to the decrease in international ophthalmology sales of 0.6 percent. The decrease in international ophthalmology sales was primarily due to decreased sales of ophthalmic base business capital and disposables, partially offset by increased sales from M.I.S.S.
Gross Profit
Gross profit as a percentage of net sales was 56.1 percent in the first nine months of fiscal 2014 compared to 50.5 percent for the same period in fiscal 2013. Gross profit as a percentage of net sales for the first nine months of fiscal 2014 compared to the first nine months of fiscal 2013 increased 5.6 percentage points. Gross profit margin for the first nine months of fiscal 2013 was impacted by the three following factors: (i) an approximate $1.6 million write-off of excess inventory and its associated labor and overhead negatively impacted our margin by 3.6 percentage points; (ii) weak demand for both our disposables and capital equipment reduced our ability to absorb labor and overhead costs and negatively impacted margin by 1.4 percentage points; and (iii) the decreased benefit from deferred revenue negatively impacted margin by 0.5 percentage points. The inventory write-off, the weak demand for our disposables and the decreased benefit from deferred revenue did not recur during the first nine months of 2014.
Operating Expenses (dollars in thousands)
|
|
|
Nine Months Ended
April 30, 2014
|
|
|
Nine Months Ended April 30, 2013
|
|
|
|
|
Dollars
|
|
|
Percent of Sales
|
|
|
Dollars
|
|
|
Percent of Sales
|
|
|
Research & Development Expenses
|
|
$
|
4,012
|
|
|
|
8.6
|
%
|
|
$
|
2,660
|
|
|
|
5.9
|
%
|
|
Sales & Marketing Expenses
|
|
|
10,655
|
|
|
|
22.8
|
%
|
|
|
10,367
|
|
|
|
23.1
|
%
|
|
General & Administrative Expenses
|
|
|
8,240
|
|
|
|
17.6
|
%
|
|
|
7,999
|
|
|
|
17.8
|
%
|
|
Exit Costs
|
|
|
578
|
|
|
|
1.2
|
%
|
|
|
--
|
|
|
|
--
|
%
|
|
Medical Device Excise Tax
|
|
|
323
|
|
|
|
0.7
|
%
|
|
|
160
|
|
|
|
0.4
|
%
|
R&D as a percentage of net sales was 8.6 percent and 5.9 percent for the first nine months of fiscal 2014 and 2013, respectively. R&D investment increased $1.4 million in the first nine months of fiscal 2014 compared to the same period in fiscal 2013. The Company’s pipeline included approximately 26 active projects in various stages of completion as of April 30, 2014. The Company’s R&D investment is driven by the opportunities to accelerate new products to meet the needs of its surgeon customers and address the demands of the market. This results in an investment rate that the Company believes is comparable to such spending by other medical device companies. The Company expects to invest in R&D at a rate of approximately 6.0 to 8.0 percent of net sales over the next few years.
Sales and marketing expenses increased $288,000 to approximately $10.7 million, or 22.8 percent of net sales, for the first nine months of fiscal 2014 compared to $10.4 million, or 23.1 percent of net sales, for the first nine months of fiscal 2013. The increase is primarily due to the addition of the M.I.S.S. personnel in conjunction with the acquisition.
General and administrative expenses increased by approximately $241,000 to $8.2 million, or 17.6 percent of net sales, in the first nine months of fiscal 2014 compared to $8.0 million, or 17.8 percent of net sales, for the first nine months of fiscal 2013. The increase is primarily due to the addition of the M.I.S.S. personnel in conjunction with the acquisition and various other expense increases.
Exit costs were $578,000, or 1.2 percent for net sales, for the first nine months of fiscal 2014 due to the closure of the King of Prussia location. Exit costs consisted primarily of the retirement obligation due to Dr. Malis, the Company’s former Executive Vice President and Chief Scientific Officer and other severance obligations.
Medical device excise tax was $323,000, or 0.7 percent of net sales, for the first nine months of fiscal 2014 compared to $160,000, or 0.4% of net sales, for the first nine months of fiscal 2013 as the Company began being assessed the medical device tax in January 2013.
Other Income/(Expenses)
Other income for the first nine months of fiscal 2014 was $7,000 as compared to other expense of $23,000 for the first nine months of fiscal 2013.
Operating Income, Income Taxes and Net Income
Operating income for the first nine months of fiscal 2014 increased $917,000 to $2.4 million as compared to the comparable 2013 fiscal period. The increase in operating income was primarily due to a 4.1 percent increase in sales and a 7.7 percent decrease in cost of sales (as detailed in the Gross Profit section above), resulting in a $3.5 million increase in gross profit. The increase in gross margin was partially offset by a 50.8 percent increase in R&D expenses, a 2.8 percent increase in sales and marketing expenses, a 3.0 percent increase in general and administrative expenses, a 101.9 percent increase in medical device excise taxes and $578,000 in exit costs associated with the closures of the King of Prussia location.
The Company recorded a $781,000 tax provision on pre-tax income of $2.4 million, a 32.1 percent tax provision, in the first nine months ended April 30, 2014. In the first nine months ended April 30, 2013, the Company recorded a $366,000 tax provision on pre-tax income of $1.5 million, a 24.6 percent tax provision. The effective tax rate for fiscal 2013 was impacted by the re-enactment of the Research and Experimentation credit from December 2011.
Net income increased by $532,000 to $1.7 million for the first nine months of fiscal 2014 from net income of $1.1 million for the same period in fiscal 2013. The increase in net income was primarily due to the increase in operating income discussed above. Basic and diluted earnings per share for the first nine months of fiscal 2014 was $0.07 as compared to $0.04 in the first nine months of fiscal 2013. Basic weighted average shares outstanding increased from 25,229,250 at April 30, 2013, to 25,311,641 at April 30, 2014.
Liquidity and Capital Resources
The Company had approximately $12.8 million in cash and no interest-bearing debt as of April 30, 2014.
Working capital, including the management of inventory and accounts receivable, is a key management focus. At April 30, 2014, the Company had an average of 87 days of sales outstanding utilizing the trailing 12 months’ sales for the period ended April 30, 2014. The 87 days of sales outstanding at April 30, 2014, was 3 days unfavorable when compared to July 31, 2013, and 15 days unfavorable when compared to April 30, 2013, utilizing the trailing 12 months of sales. The increase in days of sales outstanding was due to timing of sales throughout the quarter.
At April 30, 2014, the Company had 200 days of average cost of sales in inventory on hand utilizing the trailing 12 months’ cost of sales for the period ended April 30, 2014. The 200 days of cost of sales in inventory was unfavorable to July 31, 2013, by 22 days and 12 days unfavorable to April 30, 2013, utilizing the trailing 12 months of cost of sales. The Company had invested $3.4 million in inventory for new products and new product launches at April 30, 2014. However, the Company had $921,000 in backlog as of April 30, 2014.
Cash flows provided by operating activities were $1.4 million for the nine months ended April 30, 2014, compared to cash flows provided by operating activities of approximately $1.2 million for the comparable fiscal 2013 period. The increase in cash flows of $279,000 was primarily attributable to the increase in deferred income taxes of $1.9 million, the decrease in income taxes receivable of $580,000 and the increase in net income of $532,000, offset by an increase in inventory of $1.5 million, an increase in accounts receivable of $441,000, a decrease in accounts payable of $372,000, a decrease in accrued expenses of $343,000 and an increase in prepaid expenses of $279,000.
Cash flows used in investing activities were $1.0 million for the nine months ended April 30, 2014, compared to $695,000 of cash used in investing activities for the comparable fiscal 2013 period. During the nine months ended April 30, 2014, cash additions to property and equipment were $800,000, compared to $397,000 during the nine months ended April 30, 2013. Also, during the nine months ended April 30, 2014, cash additions to patents and other intangibles were $229,000, compared to $298,000 during the nine months ended April 30, 2013.
Cash flows provided by financing activities for the nine months ended April 30, 2014 were $61,000 compared to $137,000 for the nine months ended April 30, 2013. The decrease in cash flows provided by financing activities was due to the lower amount of stock options exercised in the period.
The Company had the following committed financing arrangements as of April 30, 2014, but had no borrowings thereunder:
Revolving Credit Facility: The Company has a credit facility with a bank which allows for borrowings of up to $9.5 million with interest at an interest rate based on either the one-, two- or three-month LIBOR plus 2.00 percent and adjusting each quarter based upon our leverage ratio. As of April 30, 2014, the interest rate under the facility would have been 2.15 percent. The unused portion of the facility is charged at a rate of 0.20 percent. There were no borrowings under this facility at April 30, 2014. Outstanding amounts, if any, are collateralized by the Company’s domestic receivables and inventory. This credit facility was amended on September 30, 2013, to extend the termination date through September 30, 2016.
The facility has two financial covenants: a maximum leverage ratio of 3.75 times and a minimum fixed charge coverage ratio of 1.1 times. As of April 30, 2014, the Company’s leverage ratio was 0.56 times and the fixed charge coverage ratio was 3,050 times. Collateral availability under the line as of April 30, 2014, was approximately $9.5 million. The facility restricts the payment of dividends if, following the distribution, the fixed charge coverage ratio would fall below the required minimum.
Equipment Line of Credit: Under this credit facility, the Company may borrow up to $1.0 million, with interest at one-month LIBOR plus 3.0 percent. Pursuant to the terms of the equipment line of credit, under no circumstance shall the rate be less than 3.5 percent per annum. The unused portion of the facility is not charged a fee. There were no borrowings under this facility as of April 30, 2014. The equipment line of credit was amended on September 30, 2013, to extend the maturity date to September 30, 2016.
Management believes that cash flows from operations, together with available cash, will be sufficient to meet the Company’s working capital and capital expenditure needs for the next 12 months. In addition, the remaining deferred revenue from the Alcon settlement will flow through our statement of income over the next 12 years. However, as cash has already been collected from the 2010 Alcon settlement, it will not impact our future liquidity.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition or results of operations.
STATEMENT REGARDING FORWARD-LOOKING INFORMATION
The Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), provide a safe harbor for forward-looking statements made by or on behalf of the Company. The Company and its representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the Securities and Exchange Commission (“SEC”) and in our reports and presentations to stockholders or potential stockholders. In some cases forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties can be found in Part I, Item 1A, “Risk Factors” section of the Company’s Form 10-K for the fiscal year ended July 31, 2013.
Although we believe the expectations reflected in our forward-looking statements are based upon reasonable assumptions, it is not possible to foresee or identify all factors that could have a material effect on the future financial performance of the Company. The forward-looking statements in this report are made on the basis of management’s assumptions and analyses, as of the time the statements are made, in light of their experience and perception of historical conditions, expected future developments and other factors believed to be appropriate under the circumstances.
In addition, certain market data and other statistical information used throughout this report are based on independent industry publications. Although we believe these sources to be reliable, we have not independently verified the information and cannot guarantee the accuracy and completeness of such sources.
Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q and the information incorporated by reference in this report to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.
Critical Accounting Policies
The Company’s significant accounting policies which require management’s judgment are disclosed in our Annual Report on Form 10-K for the fiscal year ended July 31, 2013. In the first nine months of fiscal 2014, there were no changes to the significant accounting policies.
Item 3 —
Quantitative and Qualitative Disclosures about Market Risk
The Company’s primary market risks include fluctuations in interest rates and exchange rate variability.
The Company has $12.8 million in cash and cash equivalents with a substantial portion of this cash held in short-term money market funds bearing interest at 30 basis points. Interest income from these funds is subject to market risk in the form of fluctuations in interest rates. A reduction in the interest on these funds to 15 basis points would decrease the amount of interest income from these funds by approximately $19,000.
The Company currently has a revolving credit facility and an equipment line of credit facility in place. The revolving credit facility had no outstanding balance at April 30, 2014, bearing interest at a current rate of LIBOR plus 2.0 percent. The equipment line of credit facility had no outstanding balance at April 30, 2014, bearing interest at one-month LIBOR plus 3.0 percent. Interest expense from these credit facilities is subject to market risk in the form of fluctuations in interest rates. Because the current levels of borrowings are zero, there would be no market risk associated with the interest rates. The Company does not perform any interest rate hedging activities related to these two facilities.
Additionally, the Company has exposure to non-U.S. currency fluctuations through export sales to international accounts. As only approximately 11.3 percent of our sales revenue is denominated in non-U.S. currencies, we estimate that a change in the relative strength of the dollar to non-U.S. currencies would not have a material impact on the Company’s results of operations. The Company does not conduct any hedging activities related to non-U.S. currency.
Item 4 —
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has reviewed and evaluated the effectiveness of the Company’s disclosure controls and procedures as of April 30, 2014. Based on such review and evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of April 30, 2014, the disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act, (a) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (b) is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the fiscal quarter ended April 30, 2014 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Part II — Other Information
Item 1 —
Legal Proceedings
From time to time, we may become subject to litigation claims that may greatly exceed our liability insurance limits. An adverse outcome of such litigation may adversely impact our financial condition or liquidity. We record a liability when a loss is known or considered probable and the amount can be reasonably estimated. If a loss is not probable, a liability is not recorded. As of April 30, 2014, the Company has no litigation reserve recorded.
The Company’s business is subject to certain risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our common stock. For a discussion of these risks, please refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2013. In connection with its preparation of this Quarterly Report, management has reviewed and considered these risk factors and has determined that there have been no material changes to the Company’s risk factors since the date of filing the Annual Report on Form 10-K for the fiscal year ended July 31, 2013.
Item 2 —
Unregistered Sales of Equity Securities and Use of Proceeds
None
Item 3 —
Defaults Upon Senior Securities
None
Item 4 —
Mine Safety Disclosures
Not applicable
Item 5 —
Other Information
|
(b) |
There have been no material changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors since the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended January 31, 2014. |
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
|
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
|
|
Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
| |
|
|
|
101.INS
|
|
XBRL Instance Document
|
| |
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
| |
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
| |
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
| |
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
| |
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
Trademark Acknowledgements
Regarding our trademarks, the Company relies on protections from both formal registrations and common law rights. The Synergetics brand name is a registered trademark of the Company. Other trademarks used in association with the Company’s products include the diamond logo, Vision for Life, VersaVIT, VersaPACK, Core Essentials, Bullseye, Corona, Diamond Black, DDMS, Directional Laser Probe, Extendable Directional Laser Probe, Inverted Directional Laser Probe, FullView, I-Pack, Kryoptonite, Maxillum, Microfiber, Microserrated, One-Step, Photon, Photon I, Photon II, P1, P2, Pinnacle, Syntrifugal, Apex, Synerport, TruCurve and Vivid. Other trademark registrations owned by the Company include Malis, the Malis waveform logo, and Bident. Other trademarks owned by us and for which use inures to the benefit of the Company include Burst, Barracuda, Lumenator and TruMicro. All other trademarks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
SYNERGETICS USA, INC.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
June 9, 2014
|
/s/ David M. Hable
|
|
|
|
David M. Hable, President and Chief
|
|
|
|
Executive Officer (Principal Executive Officer)
|
|
|
|
|
|
|
June 9, 2014
|
/s/ Pamela G. Boone
|
|
|
|
Pamela G. Boone, Executive Vice
|
|
|
|
President, Chief Financial Officer, Secretary
|
|
|
|
and Treasurer (Principal Financial and
|
|
|
|
Principal Accounting Officer)
|
|